Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers

Pharmacogenomics

Volumn 14, Issue 13, 2013, Pages 1551-1563

  Gassó, Patricia ^a,b,c   Papagianni, Katerina ^a   Mas, Sergi ^a,b,c   De Bobadilla, Ramón Fernández ^d   Arnaiz, Joan Albert ^a,b,e   Bernardo, Miquel ^a,b,c,e   Lafuente, Amalia ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

CYP2D6; extrapyramidal symptoms; haloperidol; healthy volunteers; pharmacogenetics; randomized clinical trial

Indexed keywords

CYTOCHROME P450 2D6; HALOPERIDOL; PLACEBO; RISPERIDONE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP2D6 GENE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WAKEFULNESS;

ADULT; AREA UNDER CURVE; BASAL GANGLIA DISEASES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HALOPERIDOL; HEALTHY VOLUNTEERS; HUMANS; MALE; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84885404642     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.150     Document Type: Article

References (41)

1. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr. Clin. North Am. 16, 589-610 (1993). Interesting review of antipsychotic-induced extrapyramidal symptoms.
2. Doddi S, Rifkin A, Karajgi B et al. Blood levels of haloperidol and clinical outcome in schizophrenia. J. Clin. Psychopharmacol. 14, 187-195 (1994).
3. Forsman A, Ohman R. Studies on serum protein binding of haloperidol. Curr. Ther. Res. Clin. Exp. 21, 245-255 (1977).
4. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 48, 689-723 (2009). Interesting review summarizing the current background of CYP2D6 variability.
5. Jaen JC, Caprathe BW, Pugsley TA et al. Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and s receptors. J. Med. Chem. 36, 3929-3936 (1993).
6. Inaba T, Kovacs J. Haloperidol reductase in human and guinea pig livers. Drug Metab. Dispos. 17, 330-333 (1989).
7. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br. J. Clin. Pharmacol. 31, 655-660 (1991).
8. Llerena A, Dahl ML, Ekqvist B et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit. 14, 261-264 (1992).
9. Llerena A, Alm C, Dahl ML et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug. Monit. 14, 92-97 (1992).
10. Suzuki A, Otani K, Mihara K et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 7, 415-418 (1997).
11. Mihara K, Suzuki A, Kondo T et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin. Pharmacol. Ther. 65, 291-294 (1999).
12. Brockmöller J, Kirchheiner J, Schmider J et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 72, 438-452 (2002).
13. Park JY, Shon JH, Kim KA et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J. Clin. Psychopharmacol. 26, 135-142 (2006).
14. Panagiotidis G, Arthur HW, Lindh JD et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: Impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther. Drug Monit. 29, 417-422 (2007).
15. Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur. J. Clin. Pharmacol. 55, 599-604 (1999). In vitro study of the implications of different CYPs on haloperidol metabolism.
16. Someya T, Suzuki Y, Shimoda K et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population. Psychiatry Clin. Neurosci. 53, 593-597 (1999).
17. Shimoda K, Morita S, Yokono A et al. CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther. Drug Monit. 22, 392-396 (2000).
18. Ohnuma T, Shibata N, Matsubara Y et al. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br. J. Clin. Pharmacol. 56, 315-320 (2003).
19. Nyberg S, Farde L, Halldin C et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry 152, 173-178 (1995).
20. Roh HK, Chung JY, Oh DY et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br. J. Clin. Pharmacol. 52, 265-271 (2001).
21. Chang WH, Lam YW, Jann MW et al. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology (Berl.) 106, 517-522 (1992).
22. Lane HY, Lin HN, Hu OY et al. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry 21, 299-311 (1997).
23. Mas S, Bernardo M, Gassó P et al. A functional variant provided further evidence for the association of ARVCF with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153, 1052-1059 (2010).
24. Mas S, Gassò P, Alvarez S et al. Intuitive pharmacogenetics: Spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J. 12, 255-259 (2012).
25. Crescenti A, Mas S, Gasso P et al. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a spanish population through multiplex long-PCR and minisequencing multiplex sinfle base extension (SBE) analysis. Clin. Exp. Pharmacol. Physiol. 34, 992-997 (2007).
26. Corripio I, Ferreira A, Portella MJ et al. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: Iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Res. 201, 73-77 (2012).
27. Simpson GM, Angus JW. A rating scale for extra-pyramidal side effects. Acta Psychiatr. Scand. Suppl. 212, 11-19 (1970).
28. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676 (1989).
29. Middelkoop HA, Van Dam EM, Smilde-Van Den Doel DA et al. 45-hour continuous quintuple-site actimetry: Relations between trunk and limb movements and effects of circadian sleep-wake rhythmicity. Psychophysiology 34, 199-203 (1997).
30. Ventura J, Lukoff D, Nuechterlein KH. Appendix 1: Brief Psychiatric Rating Scale Expanded Version (4.0) scales, anchor points, and administration manual. Int. J. Meth. Psychiatr. Res. 3, 227-243 (1993).
31. Andreasen NC. Modified Scale for the Assessment of Negative Symptoms (SANS). University of Iowa Press, IA, USA (1984).
32. Artaloytia JF, Arango C, Lahti A et al. Negative signs and symptoms secondary to antipsychotics: A double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am. J. Psychiatry 163, 488-493 (2006).
33. Jaeger J, Bitter I, Czobor P et al. The measurement of subjective experience in schizophrenia: The Subjective Deficit Syndrome Scale. Compr. Psychiatry 31, 216-226 (1990).
34. Bond AJ, James DC, Lader MH. Sedative effects on physiological and psychological measures in anxious patients. Psychol. Med. 4, 374-380 (1974).
35. Burgyone K, Aduri K, Ananth J, Parameswaran S. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr. Pharm. Des. 10, 2239-2248 (2004).
36. Shin JG, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by haloperidol metabolites: Stereoselective inhibition by reduced haloperidol. Br. J. Clin. Pharmacol. 51, 45-52 (2001).
37. Ackenheil M, Weber K. Differing response to antipsychotic therapy in schizophrenia: Pharmacogenomic aspects dialogues. Clin. Neurosci. 6, 71-77 (2004).
38. Shim JC, Kelly DL, Kim YH et al. Fluoxetine augmentation of haloperidol in chronic schizophrenia. J. Clin. Psychopharmacol. 23, 520-522 (2003).
39. LLerena A, Berecz R, Dorado P et al. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 783, 213-219 (2003).
40. Walther S, Horn H, Koschorke P et al. Increased motor activity in cycloid psychosis compared to schizophrenia. World J. Biol. Psychiatry 10, 746-751 (2009).
41. Kiang M, Daskalakis ZJ, Christensen BK et al. Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. J. Psychiatry Neurosci. 28, 293-299 (2003).